Reduced plasma albumin predicts type 2 diabetes and is associated with greater adipose tissue macrophage content and activation.
Adipose tissue
Inflammation
Plasma albumin
Type 2 diabetes
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
10
2018
accepted:
31
01
2019
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
Plasma albumin is reduced during inflammation. Obesity, a strong risk factor for type 2 diabetes (T2D), is associated with adipose tissue inflammation. However, whether albumin is associated with adipose tissue inflammation and whether it predicts T2D are unclear. Adults (predominantly American Indian) from a longitudinal study were included. Macrophage content and gene expression related to recruitment/activation were measured from subcutaneous adipose tissue (n = 51). The relationship between plasma albumin and adiposity (dual-energy X-ray absorptiometry or hydrodensitometry), glucose (oral glucose tolerance test), insulin action (hyperinsulinemic-euglycemic clamp), and insulin secretion (intravenous glucose tolerance test) were evaluated (n = 422). Progression to T2D was evaluated by Cox regression (median follow-up 8.8 years; 102 progressors). Albumin was associated with macrophage markers including C1QB (r = - 0.30, p = 0.04), CSF1R (r = - 0.30, p = 0.03), and CD11b (r = - 0.36, p = 0.01). Albumin was inversely associated with body fat percentage (r = - 0.14, p = 0.003), fasting plasma glucose (r = - 0.17, p = 0.0003), and 2 h plasma glucose (r = - 0.11, p = 0.03), and was reduced in impaired glucose regulation compared with normal glucose regulation (mean ± SD: 39.4 ± 3.6 g/l and 40.1 ± 3.9 g/l, respectively; p = 0.049). Albumin predicted T2D, even after adjustment for confounders (HR, 0.75; 95% CI 0.58-0.96; p = 0.02; per one SD difference in albumin). Reduced albumin is associated with an unfavorable metabolic profile, characterized by increased adipose tissue inflammation, adiposity, and glucose, and with an increased risk for T2D.
Sections du résumé
BACKGROUND
BACKGROUND
Plasma albumin is reduced during inflammation. Obesity, a strong risk factor for type 2 diabetes (T2D), is associated with adipose tissue inflammation. However, whether albumin is associated with adipose tissue inflammation and whether it predicts T2D are unclear.
METHODS
METHODS
Adults (predominantly American Indian) from a longitudinal study were included. Macrophage content and gene expression related to recruitment/activation were measured from subcutaneous adipose tissue (n = 51). The relationship between plasma albumin and adiposity (dual-energy X-ray absorptiometry or hydrodensitometry), glucose (oral glucose tolerance test), insulin action (hyperinsulinemic-euglycemic clamp), and insulin secretion (intravenous glucose tolerance test) were evaluated (n = 422). Progression to T2D was evaluated by Cox regression (median follow-up 8.8 years; 102 progressors).
RESULTS
RESULTS
Albumin was associated with macrophage markers including C1QB (r = - 0.30, p = 0.04), CSF1R (r = - 0.30, p = 0.03), and CD11b (r = - 0.36, p = 0.01). Albumin was inversely associated with body fat percentage (r = - 0.14, p = 0.003), fasting plasma glucose (r = - 0.17, p = 0.0003), and 2 h plasma glucose (r = - 0.11, p = 0.03), and was reduced in impaired glucose regulation compared with normal glucose regulation (mean ± SD: 39.4 ± 3.6 g/l and 40.1 ± 3.9 g/l, respectively; p = 0.049). Albumin predicted T2D, even after adjustment for confounders (HR, 0.75; 95% CI 0.58-0.96; p = 0.02; per one SD difference in albumin).
CONCLUSIONS
CONCLUSIONS
Reduced albumin is associated with an unfavorable metabolic profile, characterized by increased adipose tissue inflammation, adiposity, and glucose, and with an increased risk for T2D.
Identifiants
pubmed: 30774722
doi: 10.1186/s13098-019-0409-y
pii: 409
pmc: PMC6367730
doi:
Types de publication
Journal Article
Langues
eng
Pagination
14Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK026687
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK066525
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 DK069015
Pays : United States
Références
Lancet. 1999 May 15;353(9165):1649-52
pubmed: 10335783
J Clin Invest. 1999 Sep;104(6):787-94
pubmed: 10491414
Am J Clin Nutr. 2000 Jul;72(1):89-95
pubmed: 10871566
Diabetes. 2002 Feb;51(2):455-61
pubmed: 11812755
Diabetes. 2003 Feb;52(2):492-8
pubmed: 12540626
Obes Res. 2003 Jun;11(6):699-708
pubmed: 12805391
Diabetes Care. 2003 Nov;26(11):3160-7
pubmed: 14578255
Diabetes Care. 2004 Mar;27(3):813-23
pubmed: 14988310
J Am Diet Assoc. 2004 Aug;104(8):1258-64
pubmed: 15281044
Diabetes Metab Res Rev. 2007 May;23(4):304-10
pubmed: 17001619
Obesity (Silver Spring). 2008 Jun;16(6):1370-6
pubmed: 18356828
Diabetes. 2009 Feb;58(2):385-93
pubmed: 19008342
Int Arch Allergy Immunol. 2010;153(2):207-14
pubmed: 20413989
Diabetes Metab Rev. 1990 Feb;6(1):1-27
pubmed: 2192853
J Proteome Res. 2012 Feb 3;11(2):1391-6
pubmed: 22181049
J Immunol. 2012 Apr 15;188(8):3716-23
pubmed: 22422887
PLoS One. 2012;7(12):e51496
pubmed: 23284703
Nat Rev Endocrinol. 2013 Dec;9(12):750-5
pubmed: 23835371
Nat Rev Drug Discov. 2014 Jun;13(6):465-76
pubmed: 24854413
Diabetologia. 2015 May;58(5):961-7
pubmed: 25680582
Diabetes Care. 2016 Feb;39(2):271-7
pubmed: 26681716
Mol Cell Proteomics. 2016 Jun;15(6):2011-20
pubmed: 27056913
PLoS One. 2017 Apr 21;12(4):e0176209
pubmed: 28430803
Expert Rev Proteomics. 2017 Aug;14(8):677-689
pubmed: 28689445
N Engl J Med. 1988 May 12;318(19):1217-25
pubmed: 3283552
Kidney Int. 1988 Mar;33(3):673-6
pubmed: 3367558
Am J Physiol. 1985 Nov;249(5 Pt 1):E447-53
pubmed: 3904479
J Clin Endocrinol Metab. 1965 Oct;25(10):1375-84
pubmed: 5320561
Am J Physiol. 1983 Jul;245(1):C133-43
pubmed: 6346895
J Clin Invest. 1983 Feb;71(2):236-47
pubmed: 6822663
Am J Epidemiol. 1978 Dec;108(6):497-505
pubmed: 736028
Am J Clin Nutr. 1995 Oct;62(4):730-4
pubmed: 7572700
Ann Epidemiol. 1995 May;5(3):186-91
pubmed: 7606307
J Clin Endocrinol Metab. 1995 May;80(5):1571-6
pubmed: 7745002
N Engl J Med. 1993 Dec 30;329(27):1988-92
pubmed: 8247074
Diabetes Care. 1993 Jan;16(1):216-27
pubmed: 8422779
Obes Res. 1996 Nov;4(6):583-600
pubmed: 8946445
J Clin Endocrinol Metab. 1976 Jun;42(6):1168-75
pubmed: 932179